Related Experiment Videos
Does pharmacologic coronary flow reserve reflect vasodilator responsiveness to increased myocardial demand in humans?
J D Rossen1, P J Nahser, H Oskarsson
1Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, USA.
Insights
Maximal pharmacologic coronary flow reserve does not adequately predict coronary vasodilation during increased myocardial demand in nonstenotic arteries. This finding is crucial for understanding coronary microcirculation and metabolic responses.
Area of Science:
- Cardiovascular physiology
- Coronary microcirculation research
- Diagnostic imaging and hemodynamics
Background:
- Coronary microcirculation is assessed during cardiac catheterization using vasodilators.
- The link between maximal vasodilation and flow changes due to metabolic demand is not well understood.
Purpose of the Study:
- To investigate the relationship between maximal pharmacologic coronary flow reserve and metabolic coronary vasodilation.
- To evaluate coronary vasodilation in nonstenotic coronary arteries under increased myocardial demand.
Main Methods:
- Intracoronary Doppler velocimetry used to assess coronary blood flow responses.
- Maximal vasodilation induced by intracoronary adenosine or papaverine.
- Myocardial demand increased via atrial pacing or dobutamine infusion.
Main Results:
- Maximal pharmacologic coronary flow reserve averaged 3.2.
- Coronary flow velocity increased with atrial pacing (32%) and dobutamine infusion (135%).
- No correlation found between pharmacologic flow reserve and flow changes during pacing or dobutamine stress.
Conclusions:
- Maximal pharmacologic coronary flow reserve is insufficient to assess coronary vasodilation during increased metabolic demand.
- Current methods may not fully capture the dynamic response of nonstenotic coronary arteries.
- Further research needed to refine assessment of coronary microvascular function.
Objective:
To assess the relationship between maximal pharmacologic coronary flow reserve and metabolic coronary vasodilation in nonstenotic coronary arteries.
Background:
Evaluation of the coronary microcirculation in humans during cardiac catheterization is commonly performed by assessment of coronary hemodynamics during administration of potent coronary vasodilators. However, the relationship between maximal pharmacologic vasodilation and flow increases occurring in response to increased myocardial demand has not been evaluated.
Methods:
The coronary blood flow responses to a maximally dilating dose of intracoronary adenosine or papaverine and to a standardized atrial pacing stress were assessed in 49 patients using intracoronary Doppler velocimetry. The blood flow responses to a maximally dilating dose of intracoronary adenosine and to intravenous infusion of dobutamine were determined in 13 patients.
Results:
The maximal pharmacologic coronary flow reserve averaged 3.2 +/- 0.1 (mean +/- SEM). The coronary blood flow velocity increased by 32 +/- 3% during atrial pacing, and the change in coronary flow velocity was correlated with the change in the mean arterial pressure x heart rate product during pacing. Regression analysis revealed no relationship between the pharmacologic coronary flow reserve and the change in coronary flow velocity during atrial pacing or the response of the flow to pacing normalized with respect to the magnitude of stress reflected by the change in rate x pressure product. The coronary blood flow velocity increased by 135 +/- 16% during dobutamine infusion. Regression analysis revealed no relationship between the pharmacologic coronary flow reserve and the change in coronary flow velocity during dobutamine infusion.
Conclusions:
Knowledge of the maximal pharmacologic coronary flow reserve is an inadequate surrogate for assessment of coronary vasodilation in response to increases in myocardial metabolic demand in nonstenotic arteries.